Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment

Despite treatment of patients with metastatic colorectal cancer (mCRC) with bevacizumab plus chemotherapy, response rates are modest and there are no biomarkers available that will predict response. The aim of this study was to assess if markers associated with three interconnected cancer-associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Noonan, Sinead A., Morrissey, Maria E., Martin, Petra, Biniecka, Monika, Ó'Meachair, Shane, Maguire, Aoife, Tosetto, Miriam, Nolan, Blathnaid, Hyland, John, Sheahan, Kieran, O'Donoghue, Diarmuid, Mulcahy, Hugh, Fennelly, David, O'Sullivan, Jacintha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828217/
https://www.ncbi.nlm.nih.gov/pubmed/29535825
http://dx.doi.org/10.18632/oncotarget.24276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828217/
https://www.ncbi.nlm.nih.gov/pubmed/29535825
http://dx.doi.org/10.18632/oncotarget.24276

Ejemplares similares